U.S. Federal Circuit Court Affirms Judgment for Allergan Inc. and Roche Palo Alto against Apotex Inc., Apotex Corp.., and Novex Pharma in Ketorolac Patent Infringement Lawsuit

Published: Apr 12, 2007

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) announced today that the United States Court of Appeals for the Federal Circuit has affirmed a favorable ruling for Allergan and Roche Palo Alto, LLC, formerly known as Syntex (U.S.A.) LLC, in a patent infringement lawsuit against Apotex, Inc., Apotex Corp., and Novex Pharma (the “Defendants”) preventing the Defendants from obtaining U.S. Food and Drug Administration approval to market a generic version of Allergan’s product ACULAR® (ketorolac tromethamine ophthalmic solution) 0.5% and enjoining the Defendants from manufacturing or selling the same.

Back to news